IHM-GBA
Based in Guanghzou, China, IHM-GBA is an innovation center focusing on high performance medical device. We are seeking global opportunities of bringing disruptive technologies to the Chinese market. We invest in and partner with startups that are interested in exploring China and use our resources to commercialize their products.
Mr shu zeng
DirectorINOVOTION
Our Fast, Sensitive, Reliable and Affordable assay will save you time and money, to give you a clear competitive advantage.
This breaking-thought technology, based on chick embryo, provides early analysis of your anti-cancer treatments before the classical preclinical stages. By eliminating low-value molecules early, INOVOTION accelerates your drug discovery process, increases your R&D productivity and reduces its costs.
It’s rapid Go/No Go decision with multi-cancer screening capacities.
This next generation of in vivo efficacy and toxicity tests covers fours main aspects:
- EFFICACY assays for your treatments in oncology and immuno-oncology
- EARLY TOXICITY assays for your drug candidates
- TARGET VALIDATION in oncology
- MULTI-CANCER SCREENING to (re)positioning your treatment
Philippe Fornies
Head of Business DevelopmentiX Biopharma Ltd
Ms Yuhuan Wang
Senior BD ManagerKitov Pharma
company advancing first in class oncology therapies. We currently have one FDA
approved drug, Consensi™, and two oncology therapeutic candidates, CM-24 and NT-219:
• CM-24 is a clinical stage mAb targeting CEACAM1, a novel immune checkpoint inhibitor with high potential to treat multiple oncology indications. CEACAM1 is associated with angiogenesis, is an
inter-cellular adhesion regulator and acts as a TIM-3 activator. High CEACAM1 expression is known to be associated with poor disease prognosis in a number of tumor types. Thus, blocking CEACAM1 with CM24 is associated with anti-angiogenic, immune access, and checkpoint release mechanisms. In a phase I
clinical study, CM-24 demonstrated a good safety profile and promising efficacy signals. We are developing CM-24 in a clinical collaboration with Bristol
Myers-Squibb for Phase 1/2 trial combining CM-24 with nivolumab in NSCLC and pancreatic cancer patients expressing high CEACAM1 levels.
• NT-219 is a first-in-class, dual inhibitor small molecule targeting IRS 1/2 and STAT3, two key signal transducers that promote cancer drug resistance. In preclinical studies, NT-219 demonstrated outstanding
efficacy in preventing acquired resistance and reversing tumor resistance when administered as a monotherapy and in combination with various oncology therapies. We are initiating first-in-man clinical trials with NT219, both as monotherapy and in combination with cetuximab (Erbitux™), with plans to expand combination studies in patients with recurrent or metastatic SCCHN cancer during 2020.
Yael Lahat
Associate Director Business DevelopmentLansen Pharmaceutical Holdings Limited
Dong Sheng
BD ManagerLEO Pharma
LEO Pharma is continuously striving to advance innovation to bring best-in-class and first-in-class medicines in medical dermatology and rare dermatological diseases to create a solid pipeline of assets. LEO Pharma’s mission is to provide people with healthy skin and is has a global dermatology reach employing approximately 6,000 employees worldwide. We serve approximately 92 million patients in 2019 with ambition to serve 125 million patients by 2025.
To realize our vision of becoming the preferred dermatology care partner improving people’s lives around the world, we are constantly looking to collaborate with other companies, Universities to offer patients with therapies that address unmet medical needs in dermatology.
We are keen for In-Licensing Assets for Global and Regional Rights for following: (1) Chinese Rights: innovative (first-in-class or best-in-class) late stage assets (Phase 3 or launched in US, EU or Japan) in medical dermatology or rare dermatological diseases (2) Global Rights: innovative (first-in-class or best-in-class) assets (Pre-clinical through phase III) in medical dermatology or rare dermatological diseases from Asian Biotech companies, Research, and/or academic institutes/universities. (3) VC companies: Who have in their portfolio, companies that have medical dermatology products in their pipeline for China or Global markets (4) Keen to Science and Tech parks in China: Who have companies conducting cutting edge research in medical dermatology
In addition we LEO Pharma has two early stage assets available for partnering.
LEO 142397 (LP0184) is an oral, super selective JAK 1 inhibitor for inflammatory diseases. Product is ready for phase 1 studies. Compound is available for global licensing or acquisition.
LEO 134310 (LP0155) is a SEGRA compound. It is topical, supersoft, non-steroidal Glucocorticoid Receptor (GR) agonist with improved systemic and local safety profile. LP0155 has demonstrated efficacy in clinical phase 1 studies. Compound is available for global licensing or acquisition.
Rachit Vohra
Business Development DirectorLuoxin Pharma
Angelina Zhang
BD DirectorMedGene Therapeutics
MEDGENE is a T cell therapy biotech start-up (late pre-clinical stage) based in Maryland, USA.
- Focused on developing PD1+ peripheral blood-derived, tumor-reactive CD8+ T cell (PBTL) therapies as a platform for the treatment of solid tumors that are rare, orphan, and have critical (high) unmet need
- PBTL is a simpler, smarter version of TIL
- PBTL is a process to select highly tumor-reactive T cells from a patient's peripheral blood based on the expression of two specific T cell surface markers: PD-1 and/or TIM-3
- After selection, expanded to large quantities, it gets re-infused into the patient via the ACT regimen
- PBTL technology has been patented (issued) already in the US, China, the EU, Japan, Australia
- MEDGENE has robust Clinical Development Pipelines (currently, 9 as monotherapy way)
- Looking for funding for entering Phase 1/2 in three pipelines in the US
- Looking for partnering for the Asian market (China, Japan, South Korea)